{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:43:45Z","timestamp":1767339825250,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 107-2313-B0005-045","MOST 106-2311-B-002-028-MY3"],"award-info":[{"award-number":["MOST 107-2313-B0005-045","MOST 106-2311-B-002-028-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006477","name":"National Taiwan University","doi-asserted-by":"crossref","award":["108L7842"],"award-info":[{"award-number":["108L7842"]}],"id":[{"id":"10.13039\/501100006477","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic inflammation has been implicated in sarcomagenesis. Among various factors, activation of nuclear factor-kappa B (NF-\u03baB) signaling pathway has been documented being able to target genes associated with tumor progression and up-regulate the expression of tumor-promoting cytokines and survival genes in several human solid tumors. Feline injection sites sarcomas (FISS) are malignant entities derived from the mesenchymal origin. The disease has been considered to be associated with vaccine adjuvant, aluminum, which serves as a stimulus continuously inducing overzealous inflammatory and immunologic reactions. To understand the contribution of NF-\u03baB in FISS, detection of activated NF-\u03baB in paraffin-embedded specimens, in vitro establishment of primary cells derived from FISS, and evaluation of the effects of the NF-\u03baB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on primary tumor cells were conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this study, nuclear expression of NF-\u03baB p65 was detected in 83.3% of FISS cases and not correlated with tumor grading, sex, and age. Primary cells derived from FISS in three cats exhibiting same immunohistochemical characteristics as their original tumor were successfully established. The NF-\u03baB inhibitor, DHMEQ, was able to prevent nuclear translocation of NF-\u03baB p65, inhibit cell proliferation, migration, and colonization in dosage-dependent manners, and induce cell apoptosis in these primary FISS cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>High expression rate of nuclear NF-\u03baB p65 in FISS cases and dose-dependent inhibitory effects on the growth of FISS primary cells treated with NF-\u03baB inhibitor suggested that NF-\u03baB might be a potential molecular therapeutic target for FISS.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12917-019-2100-9","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T18:01:55Z","timestamp":1572026515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Role of nuclear factor-kappa B in feline injection site sarcoma"],"prefix":"10.1186","volume":"15","author":[{"given":"Cheng-Shun","family":"Hsueh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Ho","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hsin","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason Lih-Seng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chian-Ren","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Fei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hue-Ying","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-1886","authenticated-orcid":false,"given":"Hui-Wen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"2100_CR1","first-page":"5391","volume":"52","author":"MJ Hendrick","year":"1992","unstructured":"Hendrick MJ, Goldschmidt MH, Shofer FS, Wang Y-Y, Somlyo AP. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res. 1992;52:5391\u20134.","journal-title":"Cancer Res"},{"key":"2100_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1078\/0940-2993-00307","volume":"55","author":"F Jel\u00ednek","year":"2003","unstructured":"Jel\u00ednek F. Postinflammatory sarcoma in cats. Exp Toxicol Pathol. 2003;55:167\u201372.","journal-title":"Exp Toxicol Pathol"},{"key":"2100_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0195-5616(96)50009-4","volume":"26","author":"DW Macy","year":"1996","unstructured":"Macy DW, Hendrick MJ. The potential role of inflammation in the development of postvaccinal sarcomas in cats. Vet Clin North Am Small Anim Pract. 1996;26:103\u20139.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2100_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5326\/15473317-32-2-91","volume":"32","author":"S Lester","year":"1996","unstructured":"Lester S, Clemett T, Burt A. Vaccine site-associated sarcomas in cats: clinical experience and a laboratory review (1982-1993). J Am Anim Hosp Assoc. 1996;32:91\u20135.","journal-title":"J Am Anim Hosp Assoc"},{"key":"2100_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1354\/vp.39-1-33","volume":"39","author":"S Couto","year":"2002","unstructured":"Couto S, Griffey S, Duarte P, Madewell B. Feline vaccine-associated fibrosarcoma: morphologic distinctions. Vet Pathol. 2002;39:33\u201341.","journal-title":"Vet Pathol"},{"key":"2100_CR6","first-page":"899","volume":"201","author":"RR Dubielzig","year":"1993","unstructured":"Dubielzig RR, Hawkins KL, Miller PE. Myofibroblastic sarcoma originating at the site of rabies vaccination in a cat. J Am Vet Med Assoc. 1993;201:899\u2013901.","journal-title":"J Am Vet Med Assoc"},{"key":"2100_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1939-1676.2011.00836.x","volume":"26","author":"WB Morrison","year":"2012","unstructured":"Morrison WB. Inflammation and cancer: a comparative view. J Vet Intern Med. 2012;26:18\u201331.","journal-title":"J Vet Intern Med"},{"key":"2100_CR8","doi-asserted-by":"publisher","first-page":"E130","DOI":"10.1111\/vco.12358","volume":"16","author":"M AbdelMageed","year":"2018","unstructured":"AbdelMageed M, Foltopoulou P, McNiel E. Feline vaccine-associated sarcomagenesis: is there an inflammation-independent role for aluminium? Vet Comp Oncol. 2018;16:E130\u2013E43.","journal-title":"Vet Comp Oncol"},{"key":"2100_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12192-013-0449-4","volume":"19","author":"J Radons","year":"2014","unstructured":"Radons J. Inflammatory stress and sarcomagenesis: a vicious interplay. Cell Stress Chaperones. 2014;19:1\u201313.","journal-title":"Cell Stress Chaperones"},{"key":"2100_CR10","first-page":"1165","volume":"18","author":"Y Hoki","year":"2007","unstructured":"Hoki Y, Murata M, Hiraku Y, Ma N, Matsumine A, Uchida A, Kawanishi S. 8-Nitroguanine as a potential biomarker for progression of malignant fibrous histiocytoma, a model of inflammation-related cancer. Oncol Rep. 2007;18:1165\u20139.","journal-title":"Oncol Rep"},{"key":"2100_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel B, Schmid JA. The complexity of NF-\u03baB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.","journal-title":"Mol Cancer"},{"key":"2100_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fimmu.2011.00098","volume":"2","author":"G Multhoff","year":"2012","unstructured":"Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2012;2:98.","journal-title":"Front Immunol"},{"key":"2100_CR13","first-page":"465","volume":"15","author":"K Koga","year":"2005","unstructured":"Koga K, Nabeshima K, Nishimura N, Shishime M, Nakayama J, Iwasaki H. Microvessel density and HIF-1\u03b1 expression correlate with malignant potential in fibrohistiocytic tumors. Eur J Dermatol. 2005;15:465\u20139.","journal-title":"Eur J Dermatol"},{"key":"2100_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1128\/CMR.15.3.414-429.2002","volume":"15","author":"J Caamano","year":"2002","unstructured":"Caamano J, Hunter CA. NF-\u03baB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev. 2002;15:414\u201329.","journal-title":"Clin Microbiol Rev"},{"key":"2100_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M. NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18:309\u201324.","journal-title":"Nat Rev Immunol"},{"key":"2100_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/bs.apcsb.2016.11.006","volume":"107","author":"J Durand","year":"2017","unstructured":"Durand J, Baldwin A. Targeting IKK and NF-\u03baB for therapy. Adv Protein Chem Struct Biol. 2017;107:77\u2013115.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"2100_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nm1519","volume":"13","author":"BK Park","year":"2007","unstructured":"Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ. NF-\u03baB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med. 2007;13:62\u20139.","journal-title":"Nat Med"},{"key":"2100_CR18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1016-8478(23)15088-6","volume":"14","author":"K Umezawa","year":"2002","unstructured":"Umezawa K, Chaicharoenpong C. Molecular design and biological activities of NF-kappaB inhibitors. Mol Cells. 2002;14:163\u20137.","journal-title":"Mol Cells"},{"key":"2100_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.bbrc.2008.08.148","volume":"376","author":"M Watanabe","year":"2008","unstructured":"Watanabe M, Nakashima M, Togano T, Higashihara M, Watanabe T, Umezawa K, Horie R. Identification of the RelA domain responsible for action of a new NF-\u03baB inhibitor DHMEQ. Biochem Biophys Res Commun. 2008;376:310\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"2100_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ijc.20688","volume":"114","author":"M Watanabe","year":"2005","unstructured":"Watanabe M, Dewan Z, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T. A novel NF-\u03baB inhibitor DHMEQ selectively targets constitutive NF-\u03baB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer. 2005;114:32\u20138.","journal-title":"Int J Cancer"},{"key":"2100_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1586\/14737140.3.6.793","volume":"3","author":"Y Horiguchi","year":"2003","unstructured":"Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K. Antitumor effect of a novel nuclear factor-\u03baB activation inhibitor in bladder cancer cells. Expert Rev Anticancer Ther. 2003;3:793\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2100_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hed.20304","volume":"28","author":"HY Ruan","year":"2006","unstructured":"Ruan HY, Masuda M, Ito A, Umezawa K, Nakashima T, Yasumatsu R, Kuratomi Y, Yamamoto T, Weinstein IB, Komune S. Effects of a novel NF-\u03baB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. Head Neck. 2006;28:158\u201365.","journal-title":"Head Neck"},{"key":"2100_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.canlet.2008.07.021","volume":"272","author":"K Horiuchi","year":"2008","unstructured":"Horiuchi K, Morioka H, Nishimoto K, Suzuki Y, Susa M, Nakayama R, Kawai A, Sonobe H, Takaishi H, Ozaki T. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-\u03baB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). Cancer Lett. 2008;272:336\u201344.","journal-title":"Cancer Lett"},{"key":"2100_CR24","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-04-0463","volume":"10","author":"DV Starenki","year":"2004","unstructured":"Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S. Induction of thyroid cancer cell apoptosis by a novel nuclear factor \u03baB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res. 2004;10:6821\u20139.","journal-title":"Clin Cancer Res"},{"key":"2100_CR25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.1287.11.3","volume":"11","author":"G Matsumoto","year":"2005","unstructured":"Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K. Targeting of nuclear factor \u03baB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 2005;11:1287\u201393.","journal-title":"Clin Cancer Res"},{"key":"2100_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2174\/1871520617666171113151335","volume":"18","author":"PM Ramos","year":"2018","unstructured":"Ramos PM, Pezuk JA, Castro-Gamero AM, Oliveira HF, Scrideli CA, Umezawa K, Tone LG. Antineoplastic effects of NF-\u039aB inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) alone and in co-treatment with radio-and chemotherapy in medulloblastoma cell lines. Anti Cancer Agents Med Chem. 2018;18:541\u20139.","journal-title":"Anti Cancer Agents Med Chem"},{"key":"2100_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3324\/haematol.2017.165381","volume":"103","author":"CP Simon-Gabriel","year":"2018","unstructured":"Simon-Gabriel CP, Foerster K, Saleem S, Bleckmann D, Benkisser-Petersen M, Thornton N, Umezawa K, Decker S, Burger M, Veelken H. Microenvironmental stromal cells abrogate NF-\u03baB inhibitor-induced apoptosis in chronic lymphocytic leukemia. Haematologica. 2018;103:136\u201347.","journal-title":"Haematologica"},{"key":"2100_CR28","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1038\/bjc.2014.251","volume":"110","author":"H Nishio","year":"2014","unstructured":"Nishio H, Yaguchi T, Sugiyama J, Sumimoto H, Umezawa K, Iwata T, Susumu N, Fujii T, Kawamura N, Kobayashi A. Immunosuppression through constitutively activated NF-\u03baB signalling in human ovarian cancer and its reversal by an NF-\u03baB inhibitor. Br J Cancer. 2014;110:2965\u201374.","journal-title":"Br J Cancer"},{"key":"2100_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2460\/javma.2000.216.58","volume":"216","author":"AE Hershey","year":"2000","unstructured":"Hershey AE, Sorenmo KU, Hendrick MJ, Shofer FS, Vail DM. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986\u20131996). J Am Vet Med Assoc. 2000;216:58\u201361.","journal-title":"J Am Vet Med Assoc"},{"key":"2100_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/1098612X17717882","volume":"20","author":"N M\u00fcller","year":"2017","unstructured":"M\u00fcller N, Kessler M. Curative-intent radical en bloc resection using a minimum of a 3 cm margin in feline injection-site sarcomas: a retrospective analysis of 131 cases. J Feline Med Surg. 2017;20:509\u201319. https:\/\/doi.org\/10.1177\/1098612X17717882 .","journal-title":"J Feline Med Surg"},{"key":"2100_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13028-017-0315-y","volume":"59","author":"K Zabielska-Koczyw\u0105s","year":"2017","unstructured":"Zabielska-Koczyw\u0105s K, Wojtalewicz A, Lechowski R. Current knowledge on feline injection-site sarcoma treatment. Acta Vet Scand. 2017;59:47.","journal-title":"Acta Vet Scand"},{"key":"2100_CR32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0195-5616(02)00022-0","volume":"32","author":"B S\u00e9guin","year":"2002","unstructured":"S\u00e9guin B. Feline injection site sarcomas. Vet Clin North Am Small Anim Pract. 2002;32:983\u201395.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2100_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2460\/javma.239.1.97","volume":"239","author":"HA Phelps","year":"2011","unstructured":"Phelps HA, Kuntz CA, Milner RJ, Powers BE, Bacon NJ. Radical excision with five-centimeter margins for treatment of feline injection-site sarcomas: 91 cases (1998\u20132002). J Am Vet Med Assoc. 2011;239:97\u2013106.","journal-title":"J Am Vet Med Assoc"},{"key":"2100_CR34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2460\/javma.231.5.742","volume":"231","author":"KA Hahn","year":"2007","unstructured":"Hahn KA, Endicott MM, King GK, Harris-King FD. Evaluation of radiotherapy alone or in combination with doxorubicin chemotherapy for the treatment of cats with incompletely excised soft tissue sarcomas: 71 cases (1989\u20131999). J Am Vet Med Assoc. 2007;231:742\u20135.","journal-title":"J Am Vet Med Assoc"},{"key":"2100_CR35","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/vco.12207","volume":"15","author":"N Holtermann","year":"2017","unstructured":"Holtermann N, Kiupel M, Hirschberger J. The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects. Vet Comp Oncol. 2017;15:632\u201340.","journal-title":"Vet Comp Oncol"},{"key":"2100_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1476-5829.2011.00291.x","volume":"10","author":"J Lawrence","year":"2012","unstructured":"Lawrence J, Saba C, Gogal R, Lamberth O, Vandenplas M, Hurley D, Dubreuil P, Hermine O, Dobbin K, Turek M. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. Vet Comp Oncol. 2012;10:143\u201354.","journal-title":"Vet Comp Oncol"},{"key":"2100_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/molecules22020253","volume":"22","author":"K Zabielska-Koczyw\u0105s","year":"2017","unstructured":"Zabielska-Koczyw\u0105s K, Dolka I, Kr\u00f3l M, \u017bbikowski A, Lewandowski W, Mieczkowski J, W\u00f3jcik M, Lechowski R. Doxorubicin conjugated to glutathione stabilized gold nanoparticles (au-GSH-Dox) as an effective therapeutic agent for feline injection-site sarcomas\u2014chick embryo chorioallantoic membrane study. Molecules. 2017;22:253.","journal-title":"Molecules"},{"key":"2100_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trivac.2014.11.001","volume":"4","author":"D Jas","year":"2015","unstructured":"Jas D, Soyer C, De Fornel-Thibaud P, Oberli F, Vernes D, Guigal P-M, Poulet H, Devauchelle P. Adjuvant immunotherapy of feline injection-site sarcomas with the recombinant canarypox virus expressing feline interleukine-2 evaluated in a controlled monocentric clinical trial when used in association with surgery and brachytherapy. Trials Vaccinol. 2015;4:1\u20138.","journal-title":"Trials Vaccinol"},{"key":"2100_CR39","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179.","journal-title":"Sci Rep"},{"key":"2100_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin M. Nuclear factor-\u03baB in cancer development and progression. Nature. 2006;441:431.","journal-title":"Nature"},{"key":"2100_CR41","first-page":"20","volume-title":"Cancer cell culture\u2014Methods and protocols","author":"IA Cree","year":"2001","unstructured":"Cree IA. Principles of cancer cell culture. In: Cree IA, Walker JM, editors. Cancer cell culture\u2014Methods and protocols. 2nd ed. New York: Springer; 2001. p. 20.","edition":"2"},{"key":"2100_CR42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1074\/mcp.M800258-MCP200","volume":"8","author":"C Pan","year":"2009","unstructured":"Pan C, Kumar C, Bohl S, Klingmueller U, Mann M. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteomics. 2009;8:443\u201350.","journal-title":"Mol Cell Proteomics"},{"key":"2100_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jim.2015.03.018","volume":"423","author":"O Maguire","year":"2015","unstructured":"Maguire O, O\u2019Loughlin K, Minderman H. Simultaneous assessment of NF-\u03baB\/p65 phosphorylation and nuclear localization using imaging flow cytometry. J Immunol Methods. 2015;423:3\u201311.","journal-title":"J Immunol Methods"},{"key":"2100_CR44","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1158\/1078-0432.CCR-04-2561","volume":"11","author":"K Kuroda","year":"2005","unstructured":"Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M. Prevention of cancer cachexia by a novel nuclear factor \u03baB inhibitor in prostate cancer. Clin Cancer Res. 2005;11:5590\u20134.","journal-title":"Clin Cancer Res"},{"key":"2100_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbrc.2017.02.022","volume":"485","author":"T Ukaji","year":"2017","unstructured":"Ukaji T, Lin Y, Okada S, Umezawa K. Inhibition of MMP-2-mediated cellular invasion by NF-\u03baB inhibitor DHMEQ in 3D culture of breast carcinoma MDA-MB-231 cells: a model for early phase of metastasis. Biochem Biophys Res Commun. 2017;485:76\u201381.","journal-title":"Biochem Biophys Res Commun"},{"key":"2100_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10585-012-9544-7","volume":"30","author":"K Suzuki","year":"2013","unstructured":"Suzuki K, Aiura K, Matsuda S, Itano O, Takeuchi O, Umezawa K, Kitagawa Y. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer. Clin Exp Metastasis. 2013;30:381\u201392.","journal-title":"Clin Exp Metastasis"},{"key":"2100_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2009.05.022","volume":"287","author":"JHT Wong","year":"2010","unstructured":"Wong JHT, Lui VWY, Umezawa K, Ho Y, Wong EYL, Ng MHL, Cheng SH, Tsang CM, Tsao SW, Chan ATC. A small molecule inhibitor of NF-\u03baB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett. 2010;287:23\u201332.","journal-title":"Cancer Lett"},{"key":"2100_CR48","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1182\/blood-2004-09-3646","volume":"106","author":"M Watanabe","year":"2005","unstructured":"Watanabe M, Ohsugi T, Shoda M, Ishida T, Aizawa S, Maruyama-Nagai M, Utsunomiya A, Koga S, Yamada Y, Kamihira S. Dual targeting of transformed and untransformed HTLV-1\u2013infected T cells by DHMEQ, a potent and selective inhibitor of NF-\u03baB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005;106:2462\u201371.","journal-title":"Blood"},{"key":"2100_CR49","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1080\/10428190802357071","volume":"49","author":"MI Vega","year":"2008","unstructured":"Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, Bonavida B. The NF-\u03baB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma. 2008;49:1982\u201394.","journal-title":"Leuk Lymphoma"},{"key":"2100_CR50","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/sj.bjc.6602796","volume":"93","author":"L Lessard","year":"2005","unstructured":"Lessard L, Begin L, Gleave M, Mes-Masson A, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005;93:1019\u201323.","journal-title":"Br J Cancer"},{"key":"2100_CR51","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NA Franken","year":"2006","unstructured":"Franken NA, Rodermond HM, Stap J, Haveman J, Van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315\u20139.","journal-title":"Nat Protoc"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2100-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-019-2100-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2100-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T19:22:06Z","timestamp":1721935326000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-019-2100-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1186\/s12917-019-2100-9","relation":{},"ISSN":["1746-6148"],"issn-type":[{"type":"electronic","value":"1746-6148"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"14 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving animal sample collection were performed in accordance with guidelines of Institutional Animal Care and Use Committee of National Taiwan University (NTU; Taiwan, Republic of China) and carried out under the regulation and permission of the IACUC protocol (NTU107-EL-00165) at NTU.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}